Abbreviations: CI, confidence interval; OR, odds ratio. Bold and italic: significant P-value (Po 0.05).
Cannabis induces a diverse range of subjective experiences including relaxation, anxiety, euphoria, sadness, cognitive difficulties and psychotic-like symptoms. In addition, although cannabis use is associated with an overall twofold increased risk of subsequent psychotic disorders, all individuals are not at equal risk of developing psychosis when exposed to cannabis. 1 Inconsistent results have been reported regarding the influence of variants in the catechol-O-methyltransferase (COMT) gene 2, 3 or in other genes of interest, such as brain-derived neurotrophic factor (BDNF), cannabinoid receptor 1 (CNR1) 4, 5 and more convincingly, v-Akt murine thymoma viral oncogene homolog 1 (AKT1). 6 Interindividual variability in subjective experience is already present at initiation of cannabis use and could reflect intrinsic personal characteristics. From a gene × environment perspective, we hypothesized that the propensity to experience psychotomimetic effects when first using cannabis (PEFU) is influenced by genetic factors. We conducted a large community-based survey profiling the subjective response to cannabis in unrelated healthy young students. We investigated the association of polymorphisms of interest in CNR1, AKT1, BDNF and COMT genes with PEFU and found a significant association with a functional haplotype block in CNR1.
We interviewed 3807 students (age = 19.8 ±2.5 years) during their mandatory preventive health visit in a university medical center. 44% of them had used cannabis at least once in their lifetime. Subjective experiences during first use were assessed using a 17-item self-report questionnaire (5-level rating), which has a confirmed factorial structure including one grouping psychotic-like experiences: hallucinations (visual and/or auditory) and ideas of reference (see Supplementary Material for more details). High PEFU was defined as the experience of at least one of these psychotic symptoms 'strongly' or 'very strongly' when first consuming cannabis. A psychologist directly screened a subsample of 1196 students for Caucasian origins and no personal or family psychiatric history (age = 19.8 ± 2 years). After giving their informed written consent, these subjects provided DNA using cheek swabs. Among this group, 45.5% had used cannabis at least once in their lifetime and described their first subjective experiences (n = 544; age at initiation: 15.9 ± 1.8 years) (see socio-demographic characteristics in Supplementary Table 1) .
We genotyped 10 variants of interest (CNR1: rs806379, rs1535255, rs2023239, rs1049353, rs12720071, AAT repeat; COMT: rs4680, also known as Val158Met; AKT1: rs2494732, rs1130233; BDNF: rs6265, also known as Val66Met). Allele and genotype frequencies of single nucleotide polymorphisms (SNPs) are shown in Supplementary  Table 2 . Testing associations with high PEFU was conducted using different genetic models (Supplementary Methods). We found no significant association between any of these markers and high PEFU after Bonferroni correction for multiple testing.
Interestingly, using multimarker analysis, we identified one block of linkage disequilibrium in CNR1 (rs202329, rs1535255, rs806379) (Supplementary Figure) . The haplotype omnibus test was significant (khi2 = 14.02, df = 5, P = 0.015). The haplotype trend regression with gender as a covariate showed a significant association with high PEFU (P-Bonferroni = 0.023) ( Table 1) . Carrying the 'AAA' haplotype (21.6% in cases, 34.3% in controls) was significantly protective (Odds ratio, OR = 0.26, confidence interval, CI 95%: 0.1-0.67), whereas carrying the other haplotypes conferred a high risk of PEFU.
Of note, previous reports suggest that this CNR1 haplotype block influences CNR1 functions. The 'TAG' haplotype was found to be associated with reduced CNR1 mRNA levels in 39 postmortem brains, 7 and its distribution was significantly different between multiple-substance abusers and healthy controls in several independent samples (n = 1536). 7 The 'ATT' haplotype was associated with agreeableness, neuroticism and depression scores in the general population (n = 1269). 8 Moreover, rs202329 was reported to be associated with a variation in CNR1 binding in the prefrontal cortex 9 and is in strong linkage disequilibrium with rs9444584, a highly evolutionarily conserved marker strongly involved in MAPK activation. 10 In conclusion, our results support the influence of CNR1 genetic variants on the propensity to experience psychotic symptoms when exposed to cannabis in healthy young adults, but do not support the influence of COMT, BDNF and/or AKT1 gene variants, which had previously been reported to be associated with risk of psychosis onset. [2] [3] [4] [5] [6] Differences in the outcome variable could explain the fact that we did not replicate previous results. The literature has shown that cannabinoid receptors are involved in neurodevelopment, brain maturation, and could also be involved in psychosis and addiction. By studying the psychotomimetic effects at initiation of cannabis use (i.e. at 15.9 ± 1.8 years of age) in healthy young students with no psychosis or addiction, our study focused on the influence of CNR1 gene variants in the expression of psychosis through the role of CNR1 in the brain maturation occurring during adolescence. In these young students, the association of CNR1 variants with psychotomimetic effects induced by cannabis at first use could accurately reflect the genetic risk of psychosis when exposed to cannabis, by avoiding the confounding factors of preexisting psychosis or the association of these genetic variants to psychosis or addiction. Our results should be replicated in representative samples of the general population. In addition, the predictive value of this genetic marker for developing psychotic disorders when exposed to cannabis has to be determined in prospective studies in the general population as well as in individuals who are at risk for psychosis.
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The authors declare no conflict of interest. Clozapine is a prototypical atypical antipsychotic drug. Its primary indication is for treatment-resistant schizophrenia and reduction of the risk for suicide. 1 In spite of its efficacy, the use of clozapine is markedly curtailed by its side effects such as metabolic syndrome and agranulocytosis. 2 Although metabolic syndrome is more common than agranulocytosis, it is the latter which is the major reason that clinicians and patients are reluctant to consider the use of clozapine. Clozapine-induced agranulocytosis (CIA) occurs in about 0.8% of clozapine-treated patients, generally within the first 18 weeks of treatment and is characterized by a decrease in absolute neutrophil count (ANC) below 500 cells mm . The etiologic mechanism of CIA is unknown although several hypotheses have been proposed. These include nitrenium ion-mediated apoptosis, mitochondrial oxidative stressinduced apoptosis or direct cytotoxicity against mesenchymal stromal cells in the bone marrow. In addition, an immunemediated toxicity mechanism, based on reoccurrence of agranulocytosis within several days of reexposure to clozapine in patients who have had agranulocytosis, is considered to be a likely cause (reviewed in Chowdhury et al. 2 and Opgen-Rhein and Dettling
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). Among the demographic risk factors for agranulocytosis are increased age and Asian or Finnish ancestry. Concordance of agranulocytosis has been reported in monozygotic twins and genetic polymorphisms, for example, in the major histocompatibility complex (HLA) genes (e.g. HLAB38 4 and HLA-DQB1 (6,672G>C) 5 ) have been associated with CIA (reviewed in Chowdhury et al. 2 and Opgen-Rhein and Dettling
). In this study, we have utilized exome sequencing to comprehensively identify the genetic variation in the transcribed region of the genome in Finnish patients with and without CIA. Considering that CIA is rare, it is likely that low-frequency variants may also contribute to its development.
Schizophrenia or schizoaffective disorder patients (n = 50) diagnosed according to DSM-IV (Diagnostic and Statistical Manual of Mental Disorders) criteria were included in the study. Informed consent and approval by institutional ethics review board were obtained. Cases (n = 24) were diagnosed to be suffering from severe neutropenia (threatening agranulocytosis) based on the observation of a rapid decline in the ANC to o 1,500 cells mm −3 . Of these 24 patients, 13 developed a definite agranulocytosis (ANC ⩽ 500 cells mm −3 ) despite immediate discontinuation of clozapine. Controls were matched for age and sex and came from the same region of Finland as the cases. The distribution of age, gender and clozapine dose was not significantly different between cases and controls (Supplementary Table 1 ).
The enrichment of targeted regions (consensus coding sequence definition of exons and flanking introns, ∼ 50 Mb) was carried out using the Agilent SureSelect Human All Exon 50 Mb Kit (Agilent Technologies, Santa Clara, CA, USA) and the sequencing was carried out using the Illumina HiSeq 2,000 platform (Illumina, San Diego, CA, USA). For further details see Supplementary Methods.
